Shionogi & Co. Ltd. (4507.TO) Osaka Nine Months Ended December 31 GROUP 2025 2024 Revenue Y360.68 bln Y333.60 bln Operating Profit Y148.74 bln Y129.22 bln Pretax Profit Y191.27 bln Y155.88 bln Net ...
Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...
Private credit assets under management will move from roughly $13 trillion today to close to $20 trillion in the next four ...
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD) ...
Associate Prof Nguyen Hoang Bac and Associate Prof Do Van Dung of the University of Medicine and Pharmacy at HCMC are leading ...
LogiPharma has launched the agenda for its 2026 edition, with a prestigious roster of speakers and a raft of interactive formats reflecting the event’s position as the largest and most influential ...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
London: Britain's GSK has agreed to buy RAPT Therapeutics for USD 2.2 billion, accessing the U.S. biotech's experimental ...
Co. Ltd. were involved in separate divestment transactions this week, with Shionogi buying out Pfizer Inc.’s stake in Viiv Healthcare Ltd. to lift its holding to 21.7%.
Without action, by 2050 more than 10 million people per year will die as a result of antimicrobial resistance (AMR). Preventing this outcome, however, is not just a matter of developing new ...
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results